Search > Central Centrifugal Alopecia
My employer runs this trial

Delgocitinib for Hair Loss

SM
Overseen BySharlene Martin, MPH
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Icahn School of Medicine at Mount Sinai
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).

Who Is on the Research Team?

BU

Benjamin Ungar, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Are You a Good Fit for This Trial?

Inclusion Criteria

* Participants of any gender, age 18 years or older, at the time of informed consent at Screening.
* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.
* Participant self-reports a history of at least 6 months of CA (LPP or CCCA). Diagnosis will be made clinically (according to the LPPAI10, and/or CHLG11) and/or histopathologically.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Delgocitinib

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Lichen Planopilaris (LPP)Experimental Treatment1 Intervention
Group II: Centrifugal Cicatricial Alopecia (CCCA)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials
933
Recruited
579,000+

LEO Pharma

Industry Sponsor

Trials
275
Recruited
189,000+
Christophe Bourdon profile image

Christophe Bourdon

LEO Pharma

Chief Executive Officer since 2022

Engineering degree from Université de Technologie de Compiègne

Dr. Siri Torhaug profile image

Dr. Siri Torhaug

LEO Pharma

Chief Medical Officer since 2022

MD, PhD

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.